Brokerages Set ConvaTec Group PLC (CTEC) Price Target at $236.33
ConvaTec Group PLC (LON:CTEC) has earned a consensus rating of “Hold” from the ten analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is GBX 223.88 ($2.93).
A number of research firms recently weighed in on CTEC. Peel Hunt reaffirmed a “hold” rating on shares of ConvaTec Group in a research report on Wednesday, October 3rd. Deutsche Bank reissued a “sell” rating on shares of ConvaTec Group in a research report on Friday, October 5th. Numis Securities reissued a “hold” rating on shares of ConvaTec Group in a research report on Thursday, August 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a GBX 240 ($3.14) price target on shares of ConvaTec Group in a research report on Wednesday, August 8th.
In other news, insider Frank Schulkes acquired 65,000 shares of ConvaTec Group stock in a transaction dated Monday, October 15th. The shares were acquired at an average cost of GBX 150 ($1.96) per share, for a total transaction of £97,500 ($127,401.02). Also, insider Sten Scheibye acquired 22,500 shares of ConvaTec Group stock in a transaction dated Thursday, August 2nd. The stock was purchased at an average price of GBX 223 ($2.91) per share, for a total transaction of £50,175 ($65,562.52).
The firm also recently declared a dividend, which was paid on Friday, October 12th. Shareholders of record on Thursday, September 6th were given a GBX 1.31 ($0.02) dividend. This represents a yield of 0.58%. The ex-dividend date was Thursday, September 6th. This is a boost from ConvaTec Group’s previous dividend of $0.04.
ConvaTec Group Company Profile
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes.
Featured Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.